Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07499661

Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study)

This study focuses on two serious and common medical conditions: heart failure and pulmonary embolism (a blood clot in the lungs). Heart failure happens when the heart cannot pump blood effectively, and it is one of the main reasons older adults are admitted to the hospital. Pulmonary embolism can be life-threatening and may worsen heart failure or even trigger it.

Doctors believe that pulmonary embolism may often go undetected in patients who come to the hospital with symptoms of acute heart failure, such as sudden shortness of breath. This is because both conditions can cause similar symptoms, making it difficult to tell them apart. As a result, doctors may sometimes assume the symptoms are only due to heart failure and not investigate further for a possible blood clot.

However, missing a pulmonary embolism can have serious consequences. Studies suggest that some patients with heart failure who die may actually have had an undiagnosed pulmonary embolism. Current medical guidelines recommend checking for pulmonary embolism when the cause of breathing problems is unclear, but in real-life practice, this is not always done.

The goal of this study is to find out whether pulmonary embolism is underdiagnosed in patients with suspected acute heart failure and whether systematically testing for it could improve patient outcomes.

To do this, the study will compare two approaches in several hospitals. In half of the hospitals, doctors will follow their usual practice and decide case by case whether to test for pulmonary embolism. In the other half, doctors will systematically test all eligible patients for pulmonary embolism using recommended diagnostic methods.

Adult patients admitted with recent or worsening breathing difficulties and signs of acute heart failure may be included in the study, provided they give their consent. Researchers will collect information about their symptoms, tests, diagnosis, and treatments.

Patients will be monitored during their hospital stay and for three months afterward. The study will track important outcomes such as survival, new blood clots, bleeding events, repeated hospital visits for breathing problems, and overall time spent in the hospital.

The researchers expect to include about 740 patients in total. They estimate that pulmonary embolism may be found in about 1% of patients with usual care, but up to 5% when doctors systematically look for it.

This study aims to better understand how often pulmonary embolism occurs in patients with acute heart failure and whether more systematic testing could lead to earlier diagnosis and better care. The results could help improve medical practice and reduce complications or deaths related to missed diagnoses.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Agen Hospital, Emergency department, Agen, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient (≥18 years)
  • Admission to the emergency department or cardiology unit of a participating center
  • Recent onset or worsening dyspnea and/or orthopnea
  • Diagnosis of acute heart failure defined by recent dyspnea associated with at least one of the following:
  • Bilateral pulmonary crackles on auscultation and/or peripheral edema
  • Signs of pulmonary congestion on chest X-ray or lung/cardiac ultrasound
  • Elevated natriuretic peptide levels (BNP or NT-proBNP)
  • Documented history of heart failure (known chronic heart failure or prior hospitalization for acute heart failure)
  • Patient affiliated with or beneficiary of a social security system
  • Patient able and willing to provide free, informed, and written consent

Exclusion criteria

  • Shock state suggesting cardiogenic shock and/or severe pulmonary embolism
  • Severe respiratory distress at inclusion preventing appropriate positioning or performance of imaging examinations
  • Evidence of acute coronary syndrome on electrocardiogram at admission
  • Severe renal impairment (creatinine clearance <30 mL/min)
  • Known hypersensitivity or allergy to iodinated contrast agents
  • Ongoing therapeutic anticoagulation for more than 48 hours prior to admission
  • Hospitalization for more than 48 hours prior to inclusion
  • Inability to ensure 90-day follow-up (e.g., end-of-life situation, no fixed address, patient not reachable)
  • Inadequate understanding of the French language preventing proper study information and consent
  • Pregnant, breastfeeding, or postpartum women
  • Individuals under legal protection or other vulnerable populations, including minors and protected adults, in accordance with applicable public health regulations (Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code)

Treatment and study plan

Systematic screening for pulmonary embolism in all patients using a guideline-recommended diagnostic algorithm

Diagnostic Test

In intervention centers, physicians will systematically screen all patients for pulmonary embolism (PE) using guideline-recommended algorithms. The revised Geneva score will be assessed for each patient. If clinical probability is low or moderate (≤10), highly sensitive D-dimer testing will be performed. PE will be excluded if D-dimer levels are below 500 µg/L (under 50 years) or below the age-adjusted threshold (age × 10 µg/L for patients ≥50 years).

For patients with elevated D-dimers or high clinical probability, a 4-point compression venous ultrasound will be performed. If positive, PE will be confirmed. If negative or inconclusive, CT pulmonary angiography will be conducted. All diagnostic procedures must be completed within 48 hours of admission.

Primary outcomes

  1. Rate of pulmonary embolism

    Time frame: 48 hours

    Rate of pulmonary embolism (PE) diagnosed within 48 hours after hospital admission. PE must be objectively confirmed and the diagnosis validated by an independent adjudication committee blinded to study group allocation.

Study contacts

Contact information is provided by the study sponsor or research team.

Delphine Douillet, Professor

CONTACT

[email protected]

+33 (0)2 41 35 36 27

Matthieu Le Lay

CONTACT

[email protected]

+33 (0)2 41 35 58 91

Sponsors and collaborators

Lead sponsor

University Hospital, Angers

Other Gov

Registry information

Official study title

Pulmonary Embolism in Patients With Acute Heart Failure: A Pragmatic Cluster-Randomized Trial (PEHF Study)

Acronym: PEHF

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 30, 2026
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.